US Bancorp DE Has $1.25 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

US Bancorp DE trimmed its position in Exelixis, Inc. (NASDAQ:EXEL) by 2.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,110 shares of the biotechnology company’s stock after selling 1,041 shares during the period. US Bancorp DE’s holdings in Exelixis were worth $1,248,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. First Trust Direct Indexing L.P. raised its holdings in Exelixis by 30.6% during the 3rd quarter. First Trust Direct Indexing L.P. now owns 15,532 shares of the biotechnology company’s stock worth $403,000 after buying an additional 3,642 shares during the period. New York State Teachers Retirement System raised its holdings in Exelixis by 4.8% during the 3rd quarter. New York State Teachers Retirement System now owns 439,222 shares of the biotechnology company’s stock worth $11,398,000 after buying an additional 20,008 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Exelixis by 60.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock worth $1,424,000 after buying an additional 20,641 shares during the period. Pallas Capital Advisors LLC acquired a new stake in Exelixis during the 3rd quarter worth approximately $246,000. Finally, State of Alaska Department of Revenue raised its holdings in Exelixis by 1.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 126,842 shares of the biotechnology company’s stock worth $3,290,000 after buying an additional 1,455 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Exelixis

In related news, EVP Jeffrey Hessekiel sold 20,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $25.79, for a total value of $515,800.00. Following the completion of the sale, the executive vice president now directly owns 630,325 shares of the company’s stock, valued at approximately $16,256,081.75. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Jeffrey Hessekiel sold 20,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $25.79, for a total value of $515,800.00. Following the completion of the sale, the executive vice president now directly owns 630,325 shares of the company’s stock, valued at approximately $16,256,081.75. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Dana Aftab sold 96,986 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $35.00, for a total value of $3,394,510.00. Following the completion of the sale, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at $17,463,075. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 277,281 shares of company stock valued at $8,826,761 over the last ninety days. 2.85% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

EXEL has been the topic of several research analyst reports. Bank of America raised their target price on shares of Exelixis from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, October 15th. The Goldman Sachs Group upgraded shares of Exelixis to a “strong sell” rating in a report on Tuesday, October 15th. Stifel Nicolaus lifted their price objective on shares of Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a report on Wednesday, October 16th. BMO Capital Markets lifted their price objective on shares of Exelixis from $29.00 to $36.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, Morgan Stanley lifted their price objective on shares of Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, October 11th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and an average price target of $31.44.

Exelixis Trading Up 0.8 %

Shares of NASDAQ EXEL opened at $35.80 on Friday. The stock has a 50-day moving average price of $27.87 and a two-hundred day moving average price of $24.64. Exelixis, Inc. has a 12 month low of $19.20 and a 12 month high of $36.17. The company has a market cap of $10.22 billion, a price-to-earnings ratio of 22.95, a PEG ratio of 0.87 and a beta of 0.51.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. During the same period in the prior year, the business posted $0.10 earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis. On average, sell-side analysts predict that Exelixis, Inc. will post 1.68 earnings per share for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.